Oncology for the Inquisitive Mind
@InquisitiveOnc
Followers
257
Following
288
Media
46
Statuses
329
Medical Oncology Podcast | Healthcare Provider Resource | Clinicians | Education | Novel Treatment | Dr Michael Fernando | Dr Joshua Hurwitz @docjoshie
Australia
Joined August 2022
NECTA, a phase 1 alliance, is a compelling example of how collaboration, outreach, and a patient-centric model have enabled equitable access to #phase1 trials across a state spanning 800,000 km. Listen here! https://t.co/1S41KahQQG
@AnthonyMJoshua @AOParsonson @NECTANSW
open.spotify.com
Oncology for the Inquisitive Mind · Episode
0
2
2
#ASCO25 - Gynaecological Oncology with @DrPrachiBhave Today, we have the ultimate oncologist on our show, who explores #gynaeonc to its fullest potential. Trials discussed include: #TRUST, #Rosella, #FIRST & @KeynoteA18
@EJGO_IMR @NGOR_Aus @gynae
https://t.co/Ghs2zHZMHQ
open.spotify.com
Oncology for the Inquisitive Mind · Episode
0
0
1
#ASCO25 - Lung Caner with @nedmcnamee
#lungcancer treatment continues to rapidly evolve, and this year was no different. Ned talks about pivotal studies including DELLPHI304 and Checkmate 816 @GarvanInstitute @UNSW @LungCancerEu @TheALCF
https://t.co/RXUwHWN8Jd
open.spotify.com
Oncology for the Inquisitive Mind · Episode
0
0
0
#ASCO25 - Prostate Cancer with Athony Joshua Today, we’re joined by Professor Anthony Joshua, head of Medical Oncology at St Vincent’s Health Network Sydney, @GarvanInstitute and a global leader in prostate cancer and melanoma. In this episode, Professor Joshua discusses
open.spotify.com
Oncology for the Inquisitive Mind · Episode
0
1
2
#ASCO25 - #BreastCancer with Dr Adam Brufsky We unpack game-changing insights from @ASCO 2025 and discuss #SERENA6, which examines camizestrant plus CDK4/6 inhibitors in HR-positive, ESR1-mutated breast cancer; the #DESTINYBreast09 trial, highlighting trastuzumab deruxtecan in
open.spotify.com
Oncology for the Inquisitive Mind · Episode
0
0
1
#ASCO25 - Plenary Part 2 We cover two mega-trials today, the first being SERENA-6 and the second being NIVOPOSTOP, both landmark trials with unique designs and a taste of the future of oncology and precision medicine. #breastcancer #cancer @ASCO @BCNAPinkLady #HNSCC
open.spotify.com
Oncology for the Inquisitive Mind · Episode
0
0
1
0
0
0
* #asco2025 - The Plenary Episodes* To keep it fresh, we're doing things a little differently, but rest assured, we'll bring along a global host of experts to deliver the very best. We focus on adjuvant #atezolizumab in colon cancer and the use of perioperative #durvalumab in
open.spotify.com
Oncology for the Inquisitive Mind · Episode
1
0
0
Thanks to ASCO and ECO for collaborating with COSA on fresh approach to healthy workplace cultures in contemporary systems
2
1
5
This is a major story from #ASCO25. Randomized phase 3 trial of time of day of immunotherapy infusion. Randomized to infusion before or after 3pm. Early infusion far superior: PFS 11.3 vs 5.7 HR 0.42, OS HR 0.45! Impactful, pragmatic, not costly. This should be a bigger story.
54
489
1K
Exciting advances in sclc, small but not insignificant! Good to see a focus on these difficult to treats cancers
#ASCO25 | DeLLphi-304 📌 Phase 3 trial of Tarlatamab vs chemo (topotecan/lurbinectedin/amrubicin) in 2L SCLC 🧬 DLL3-targeted T-cell engager shows impressive results: 🔹 OS: 13.6 vs 8.3 mo | HR 0.60 💥 🔹 PFS: 5.3 vs 4.3 mo RMST | HR 0.71 🔹 ORR: 35% vs 20% 🔹 12-mo OS: 53% vs
0
0
0
Interesting data in the first line, but OS still immature. Questions remain regarding toxicity and longer follow up
The curves everybody’s been waiting for. First line T-DXd + pertuzumab significantly prolonged PFS over THP for HER2+ MBC (40.7 vs 26.9 months, HR 0.56, p<0.001), doubled the rate of complete responses (15% vs 8%) and had a positive OS trend (HR 0.84). Practice changing data.
0
0
0
Multiple studies looking at neoadjuvant regimens for HER2+ early BC. Looks like THP would suffice for most stage 1 and 2, and Cb not needed. Interesting question as to whether 6 cycles / 18 weeks is > than 4 cycles / 12 weeks. @ASCO #ASCO25 @OncoAlert
3
47
82
'Are adjunctive therapies in colon cancer as good as a drug?' Powerful world-first CHALLENGE CO.21 data from #ASCO2025 today showing we can 🚨 now prescribe exercise in addition to standard treatment🚨 Time to rethink cancer $$ ➡️ #ExerciseOncology
https://t.co/KRPGUGyAp6
0
2
4
*NEW EPISODE - BLADDER CANCER* This week, we explore muscle-invasive bladder cancer (MIBC). We compare two important chemotherapy regimens. The second trial utilises immunotherapy (durvalumab) in the perioperative landscape and is the first trial to do so. How will this impact
0
0
1
Inflammatory Breast Cancer is a rare, often undiagnosed subtype of breast cancer. This week, we interview Dr Massimo Cristofinelli, a leader in this field, along with precision oncology, metastatic breast cancer and liquid biopsies from @WCM_MeyerCancer
https://t.co/ri9Fh6Tu4F
0
0
0
*NEW EPISODE* - Metastatic HR +ve Breast Cancer CDK4/6 changed the #breastcancer landscape. With more trials underway next generationxt-gen of drugs on the horizon, we revisit where it all started. #oncology
#MONARCH3
#PALOMA2
#MONALEESA2
https://t.co/TUtBbx9Kx3
open.spotify.com
Oncology for the Inquisitive Mind · Episode
0
0
0
*NEW EPISODE* - Early Triple Negative Breast Cancer We talk about the two biggest trials in #TNBC trials that have come out this decade, looking at PCR, EFS and OS! Tune in, a great way to spend your weekend :) #BreastCancer
#CREATEX
#KEYNOTE522
https://t.co/mEGpjXDYeA
open.spotify.com
Oncology for the Inquisitive Mind · Episode
0
0
1